<DOC>
	<DOCNO>NCT01630941</DOCNO>
	<brief_summary>The primary objective study effect Denosumab Bone Mineral Density , Standardised Uptake Value bone metabolism patient total hip arthroplasty . The primary hypothesis demonstrate Denosumab superior placebo .</brief_summary>
	<brief_title>Effects Denosumab Periprosthetic Bone After Total Hip Arthroplasty</brief_title>
	<detailed_description>A clinical study 64 patient , age 35-65 year , unilateral osteoarthritis hip , randomise two group patient , either receive Denosumab placebo The patient operate uncemented total hip arthroplasty Continuum acetabular cup trabecular surface ( Tantalum ) longevity Highly Cross-linked Polyethylene liner , Zimmer , Warsaw , IN , USA , CFP femoral stem Titanium surface chrome cobalt 28 mm head , Waldemar Link , Hamburg , Germany . Clinical outcome evaluate Harris Hip Score EQ-5D , Bone Mineral Density DXA , Standardised Uptake Value Fluoride tracer , PET/CT biochemical marker bone formation bone resorption analyze together conventional radiology implant position fixation .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Mobility Limitation</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>1. male female patient 3565 year age unilateral OAH require THA healthy contralateral hip 2. body weight ≤110 kg body mass index ( BMI ) ≤35 kg/m2 3. living Uppsala County 4. eligible patient give oral information , write Patient Information sign Informed Consent 1. previously bonespecific treatment , e.g . bisphosphonates , raloxifene , parathyroid hormone , strontium ranelate , last five year 2. patient systemical corticosteroid 3 month consider 3. patient diagnose malignant disease last five year know metastasis malignant disease exclude 4. patient compromised general condition American Society Anesthesiologists , ASAscore &gt; 31 regard eligible 5. patient know drug alcohol abuse regard socially dysfunctional , judged investigator , consider study 6. pregnant woman woman plan pregnancy fertile woman ( premenopausal ) without contraceptive accept study 7. patient expose frequently and/or large irradiation dos , judge investigator , must include study . 8. enrol either another investigational drug study , another investigational device study , another investigational study approve drug within 30 day prior Visit 1 current study 9. condition laboratory finding opinion Investigator make patient unsuitable inclusion ( example claustrophobia )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Osteoarthritis hip</keyword>
	<keyword>Uncemented Total Hip Arthroplasty</keyword>
	<keyword>DXA</keyword>
	<keyword>BMD</keyword>
	<keyword>PET</keyword>
	<keyword>CT</keyword>
	<keyword>Biochemical bone marker</keyword>
</DOC>